How Asia's Emerging As Biomanufacturing Powerhouse

Asia is poised to become a manufacturing powerhouse, building on its success in clinical trials and biotechnology innovations. While China has already established itself as a manufacturing leader, other countries in the region are following suit. With nations like Singapore, South Korea, and India recently launching ambitious policies to boost the sector, the region is gearing up for a significant transformation in its bio-manufacturing capabilities.

- Ayesha Siddiqui

Countries like South Korea, Singapore, and others in Asia are making strides in enhancing their bio-manufacturing capabilities. The collective effort made by the respective countries helps to position Asia as a key player in the global biopharma industry towards fostering innovation, international collaborations and investments, as well as improving the regulatory environment. According to Market Data Forecast, the Asia Pacific biopharmaceuticals market was valued at $44.3 billion in 2023 and is expected to be worth $78.69 billion by 2029 with a CAGR of 10.05 per cent from 2024 to 2029.

“Asia-Pacific has emerged as a dynamic and influential region in the global biopharma industry in recent years and this transformation is driven by a confluence of factors, from rapid economic growth and significant government investments to a highly skilled workforce and a supportive regulatory environment,” said Chua Keng Hock, Senior Vice President of Process Solutions, Asia Pacific, Life Science Business of Merck.

The support of the local government and investment are pivotal in driving the growth of the biopharma sector in Asia. “The local governments in Asia have made substantial investments in the biopharma sector, focusing on building infrastructure and creating life science hubs to foster collaboration and innovation. For example, South Korea's ‘BioHealth Industry Promotion Plan’ aims to enhance the country's biotechnology capabilities through initiatives like the National Synthetic Biology Initiative, which seeks to transition 30 per cent of the manufacturing industry to the bio-industry within a decade. Similarly, Singapore has built the Biopolis, a research and development hub, and Tuas Biomedical Park, a purpose-built estate for pharmaceutical and medical technology companies,” said Chua Keng Hock.